Table 5.

Tyrosine kinase inhibitors in epithelial ovarian carcinoma.

Drug	Generic name	Target	Current trials in ovarian carcinoma	US FDA approval (indication)	Ref.
SU11248	Sutent	VEGFR, EGFR, PDGFR, c-KIT	Phase II/III	Yes (renal)	[14]
ZD6474	Vandetanib	VEGFR, EGFR	Phase II	Yes	[21]
Sorafenib	Sorafenib	RAF-1, VEGFR-2, EGFR-3 PDGFR-β, FLT-3, c-KIT	Phase I/II/III	Yes (renal)	[16]
AZD2171	Cediranib	VEGFR-1-3, PDGFR, c-KIT	Phase I/II/III	No	[22]
GW786034	Pazopanib	VEGFR1-3, PDGFR-α/β, c-KIT	Phase II	No	[15]
PTK787	Vatalanib	VEGFR-1-3, PDGFR, c-KIT	Phase I	No	[20]
BIBF 1120	Vargatef	VEGFR, PDGFR, FGFR	Phase I	No	[17]
BMS-582664	Brivanib	VEGFR-2, FGFR	Phase I	No	[18]